Epoetin theta - Teva

Drug Profile

Epoetin theta - Teva

Alternative Names: Biopoin; Eporatio; EpoTheta-Teva

Latest Information Update: 23 May 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Ratiopharm
  • Developer Teva Pharmaceutical Industries
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 23 May 2017 No recent reports on development identified - Registered for Anaemia in Iceland and Norway (SC)
  • 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (IV) prior to February 2015
  • 06 Feb 2015 Launched for Anaemia in United Kingdom, Austria, France, Germany, Hungary, Ireland, Netherlands, Poland, Portugal, Czech Republic, Sweden, Spain and Israel (SC) prior to February 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top